Evolus, Inc. Common Stock (EOLS) Stock Price

EOLSStock

$8.88+18.09%52W

Market Cap$586.53M

P/E—

PEG Ratio—

Div yield—

Beta1.36

EOLS Share Price Chart

Favorite Metrics

Price vs S&P 500 (26W)94.58%

Price vs S&P 500 (4W)45.24%

VGM Score61.00

Book Value / Share (Quarterly)$0.09

P/TBV (Annual)11.56x

Indicated Dividend (Annual)$0.00

Revenue Growth (3Y)25.99%

Cash Flow / Share (Quarterly)$-0.68

Price vs S&P 500 (YTD)20.71%

Gross Margin (TTM)66.06%

Net Profit Margin (TTM)-14.39%

EPS (TTM)$-0.67

10-Day Avg Trading Volume1.04M

EPS Excl Extra (TTM)$-0.67

Revenue Growth (5Y)39.38%

EPS (Annual)$-0.80

ROI (Annual)-39.69%

Gross Margin (Annual)66.33%

Net Profit Margin (5Y Avg)-32.77%

Cash / Share (Quarterly)$0.76

Revenue Growth QoQ (YoY)6.74%

ROA (Last FY)-22.86%

Revenue Growth TTM (YoY)9.56%

EBITD / Share (TTM)$-0.27

ROE (5Y Avg)-308.23%

Operating Margin (TTM)-8.06%

Cash Flow / Share (Annual)$-0.78

P/B Ratio97.90x

P/B Ratio (Quarterly)126.60x

Net Income / Employee (Annual)$-154,600

EV / Revenue (TTM)2.14x

Net Interest Coverage (TTM)-1.87x

ROA (TTM)-19.42%

EPS Incl Extra (Annual)$-0.80

Current Ratio (Annual)1.90x

Quick Ratio (Quarterly)1.61x

3-Month Avg Trading Volume0.90M

52-Week Price Return18.09%

Revenue / Employee (TTM)$903,600

Tangible BV / Share (Quarterly)$0.31

P/S Ratio (Annual)1.82x

Asset Turnover (Annual)1.32x

52-Week High$9.12

Operating Margin (5Y Avg)-27.55%

EPS Excl Extra (Annual)$-0.80

CapEx CAGR (5Y)21.90%

26-Week Price Return106.51%

Quick Ratio (Annual)1.49x

13-Week Price Return35.16%

Total Debt / Equity (Annual)22.00x

Current Ratio (Quarterly)2.04x

Enterprise Value$647.24M

Revenue / Share Growth (5Y)22.42%

Asset Turnover (TTM)1.35x

Revenue / Employee (Annual)$889,700

Inventory Turnover (Annual)5.12x

Pretax Margin (Annual)-17.15%

Cash / Share (Annual)$0.83

3-Month Return Std Dev63.52%

Gross Margin (5Y Avg)64.30%

Net Income / Employee (TTM)$-130,000

ROE (Last FY)-913.07%

Net Interest Coverage (Annual)-1.40x

EPS Basic Excl Extra (Annual)$-0.80

P/FCF (TTM)50.71x

Receivables Turnover (TTM)6.06x

Total Debt / Equity (Quarterly)22.00x

EPS Incl Extra (TTM)$-0.67

Receivables Turnover (Annual)5.81x

ROI (TTM)-37.81%

P/S Ratio (TTM)1.79x

Pretax Margin (5Y Avg)-32.64%

Revenue / Share (Annual)$4.61

Tangible BV / Share (Annual)$0.56

Forward P/E72.08x

Price vs S&P 500 (52W)-0.47%

Year-to-Date Return33.53%

5-Day Price Return1.14%

EPS Normalized (Annual)$-0.80

ROA (5Y Avg)-27.43%

Net Profit Margin (Annual)-17.38%

Month-to-Date Return52.05%

Cash Flow / Share (TTM)$-1.03

EBITD / Share (Annual)$-0.41

Operating Margin (Annual)-10.99%

LT Debt / Equity (Annual)22.00x

ROI (5Y Avg)-50.30%

LT Debt / Equity (Quarterly)22.00x

EPS Basic Excl Extra (TTM)$-0.67

P/TBV (Quarterly)36.12x

P/B Ratio (Annual)126.60x

Inventory Turnover (TTM)5.88x

Pretax Margin (TTM)-14.10%

Book Value / Share (Annual)$0.09

Price vs S&P 500 (13W)33.21%

Beta1.36x

Revenue / Share (TTM)$4.63

ROE (TTM)-410.18%

52-Week Low$3.86

vGradeC

gGradeB

mGradeB

vgmGradeB

EOLS Earnings Surprise History

Quarter	Report date	EPS estimate	EPS actual	Surprise
Q2 2026	Aug 5, 2026	-$0.04	-$0.02	+52.62%(+$0.02)
Q1 2026	May 4, 2026	-$0.12	-$0.05	+57.87%(+$0.07)
Q4 2025	Mar 3, 2026	$0.04	$0.01	-64.80%(-$0.02)
Q3 2025	Nov 5, 2025	-$0.18	-$0.15	+19.38%(+$0.04)
Q2 2025	Aug 5, 2025	-$0.09	-$0.26	-175.05%(-$0.16)

EOLS Analyst Recommendations

May 2026

Jun 2026

Jul 2026

Aug 2026

4.23

Industry Peers — Pharmaceuticals(570)

Symbol	Value Score	Growth Score	Momentum Score	Price
EOLSEvolus, Inc. Common Stock	C	B	B	$8.88
LLYEli Lilly & Co.	D	B	C	$1174.61
JNJJohnson & Johnson	D	C	B	$268.04
ABBVABBVIE INC.	D	C	B	$255.48
MRKMerck & Co., Inc.	D	C	B	$148.35
NVSNovartis AG	C	C	C	$153.81
AZNAstraZeneca PLC	C	B	C	$162.70
NVONovo-Nordisk A/S	B	C	C	$45.61
ABTAbbott Laboratories	C	C	C	$112.47
PFEPfizer Inc.	C	D	B	$27.96
VRTXVertex Pharmaceuticals Inc	D	C	B	$541.69
BMYBristol-Myers Squibb Co.	B	B	B	$66.58
SNYSanofi American Depositary Shares (Each representing one-half of one ordinary share)	B	C	C	$44.82
GSKGSK plc American Depositary Shares (Each representing two Ordinary Shares)	B	C	C	$50.82
REGNRegeneron Pharmaceuticals Inc	C	C	B	$794.19
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock)	C	C	B	$18.03
TEVATeva Pharmaceutical Industries Limited American Depositary Shares	C	C	C	$36.44
ONCBeOne Medicines Ltd. American Depositary Shares	D	B	B	$366.73
RPRXRoyalty Pharma plc Class A Ordinary Shares	D	D	B	$60.85
ZTSZOETIS INC.	C	C	D	$77.34
ALNYAlnylam Pharmaceuticals, Inc.	D	A	D	$237.10
INSMInsmed, Inc.	F	A	C	$118.54
ROIVRoivant Sciences Ltd. Common Shares	D	F	B	$34.71
UTHRUnited Therapeutics Corp	C	C	B	$515.46
GMABGenmab A/S ADS	C	C	B	$33.23
VTRSViatris Inc. Common Stock	B	C	B	$16.34
ASNDAscendis Pharma A/S Ordinary Share	D	A	C	$247.91
JAZZJazz Pharmaceuticals, Inc.	B	C	B	$244.54
BBIOBridgeBio Pharma, Inc. Common Stock	F	A	B	$76.60
BMRNBioMarin Pharmaceuticals Inc	C	C	B	$64.67
MDGLMadrigal Pharmaceuticals, Inc. Common Stock	D	A	B	$533.76
CORTCorcept Therapeutics Inc.	F	C	B	$113.88
ELANElanco Animal Health Incorporated Common Stock	C	B	C	$24.11
ARWRArrowhead Research Corporation	D	A	B	$84.91
SMMTSummit Therapeutics Inc. Common Stock	F	—	D	$13.73
AXSMAxsome Therapeutics, Inc	D	B	C	$199.02
RDYDr. Reddy's Laboratories Limited American Depositary Shares	D	D	C	$12.18
IONSIonis Pharmaceuticals, Inc. Common Stock	D	D	C	$61.05
CYTKCytokinetics Inc.	F	D	C	$72.09
ABVXAbivax SA American Depositary Shares	—	—	C	$113.35
NUVLNuvalent, Inc. Class A Common Stock	—	—	B	$123.96
PRAXPraxis Precision Medicines, Inc. Common Stock	F	—	B	$344.75
PTGXProtagonist Therapeutics, Inc	F	B	B	$144.33
CRNXCrinetics Pharmaceuticals, Inc.	F	A	A	$84.84
TGTXTG Therapeutics, Inc.	D	B	B	$53.93
SYRESpyre Therapeutics, Inc. Common Stock	—	—	B	$90.36
ALKSAlkermes Inc. plc	D	C	B	$47.41
RYTMRhythm Pharmaceuticals, Inc. Common Stock	F	B	C	$107.17
ERASErasca, Inc. Common Stock	—	—	A	$18.03
TVTXTravere Therapeutics, Inc. Common Stock	F	B	A	$65.67
BLTEBelite Bio, Inc American Depositary Shares	—	—	C	$151.72

About Evolus, Inc. Common Stock

Evolus Inc commercializes Jeuveau, a purified botulinum toxin formulation used to treat moderate to severe frown lines. The company generates revenue from product sales in the United States and Europe, and from distribution partnerships in Canada. Evolus operates in the self-pay aesthetic market, targeting physicians and consumers seeking non-invasive cosmetic treatments.